Search results for " Type 2"

showing 10 items of 761 documents

New Pharmacological Opportunities for Betulinic Acid

2017

AbstractBetulinic acid is a naturally occurring pentacyclic lupane-type triterpenoid usually isolated from birch trees, but present in many other botanical sources. It is found in different plant organs, both as a free aglycon and as glycosyl derivatives. A wide range of pharmacological activities has been described for this triterpenoid, including antiviral and antitumor effects. In addition, several other interesting properties have been identified in the fields of immunity and metabolism, namely antidiabetic, antihyperlipidemic, and anti-inflammatory activities. Taken together, these latter three properties make betulinic acid a highly interesting prospect for treating metabolic syndrome…

0301 basic medicineAnti-Inflammatory AgentsPharmaceutical ScienceAntineoplastic AgentsAntiviral AgentsAnalytical Chemistry03 medical and health scienceschemistry.chemical_compoundTriterpenoidAnti-Infective AgentsBetulinic acidDrug DiscoveryAnimalsHumansHypoglycemic AgentsGlycosylBetulinic AcidDyslipidemiasHypolipidemic AgentsInflammationMetabolic SyndromePharmacologyNatural productTraditional medicineCytotoxinsOrganic ChemistryTriterpenes030104 developmental biologyDiabetes Mellitus Type 2Complementary and alternative medicinechemistryMolecular MedicinePentacyclic TriterpenesPentacyclic TriterpenesPlanta Medica
researchProduct

Low level activity thresholds for changes in NMR biomarkers and genes in high risk subjects for type 2 diabetes

2017

AbstractOur objectives were to determine if there are quantitative associations between amounts and intensities of physical activities (PA) on NMR biomarkers and changes in skeletal muscle gene expressions in subjects with high risk for type 2 diabetes (T2D) performing a 3-month PA intervention. We found that PA was associated with beneficial biomarker changes in a factor containing several VLDL and HDL subclasses and lipids in principal component analysis (P = <0.01). Division of PA into quartiles demonstrated significant changes in NMR biomarkers in the 2nd - 4th quartiles compared to the 1st quartile representing PA of less than 2850 daily steps (P = 0.0036). Mediation analysis of PA-…

0301 basic medicineBlood GlucoseMaleVery low-density lipoprotein[SDV]Life Sciences [q-bio]prévention des maladieslcsh:MedicineAdipose tissueMuscle ProteinsType 2 diabetes030204 cardiovascular system & hematologyOverweight0302 clinical medicinemaladie cardiovasculairelcsh:ScienceComputingMilieux_MISCELLANEOUSBODY-WEIGHT CHANGEMultidisciplinaryMiddle AgedMagnetic Resonance Imaging[SDV] Life Sciences [q-bio]ADIPOSE-TISSUEBiomarker (medicine)SKELETAL-MUSCLEFemalemedicine.symptombiomarqueurINSULIN-RESISTANCE ATHEROSCLEROSISAutre (Sciences du Vivant)Adultmedicine.medical_specialtydiabète de type 2expression géniqueCarbohydrate metabolismALL-CAUSEArticle03 medical and health sciencesMedical researchLIPID-METABOLISMInternal medicineDiabetes mellitusmedicineAPOLIPOPROTEIN-D POLYMORPHISMHumansObesityNUCLEAR-MAGNETIC-RESONANCEMuscle SkeletalExercisebusiness.industryMORTALITYlcsh:RLipid metabolismsurpoidsLIPOPROTEIN PARTICLE-SIZEmedicine.disease030104 developmental biologyEndocrinologyPHYSICAL-ACTIVITYDiabetes Mellitus Type 2Gene Expression Regulationlcsh:QbusinessBiomarkers
researchProduct

Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus

2021

Diabetes represents the leading risk factor for the development of cardiovascular disease (CVD). Chronic hyperglycemia and/or acute post-prandial changes in blood glucose determine an increase in reactive oxygen species (ROS), which play a fundamental role in endothelial dysfunction and in the nuclear transport of pro-atherogenic transcription factors that activate the "inflammasome". In addition, the glycemic alteration favors the formation and stabilization of atherosclerotic plaque through the mechanism of non-enzymatic glycation of different molecules, with the establishment of the so-called "advanced glycosylation end products" (AGE). Laboratory information provided by the level of bio…

0301 basic medicineBlood GlucoseNovel biomarkersDisease030204 cardiovascular system & hematologyBioinformatics03 medical and health scienceschemistry.chemical_compound0302 clinical medicineGlycationRisk FactorsDiabetes mellitusType 2 diabetes mellitusMedicineHumansEndothelial dysfunctionRisk factorMolecular BiologyGlycemicInflammationGlycationbusiness.industryType 2 Diabetes Mellitusmedicine.diseaseCardiovascular risk030104 developmental biologychemistryDiabetes Mellitus Type 2Cardiovascular DiseasesOxidative stressMolecular MedicineAdvanced glycation end-productbusinessReactive Oxygen SpeciesBiomarkers
researchProduct

Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation

2020

AbstractPurpose:Despite the therapeutic success of existing HER2-targeted therapies, tumors invariably relapse. This study aimed at identifying new mechanisms responsible for HER2-targeted therapy resistance.Experimental Design:We have used a platform of HER2-targeted therapy–resistant cell lines and primary cultures of healthy and tumor-associated fibroblasts (TAF) to identify new potential targets related to tumor escape from anti-HER2 therapies.Results:We have shown that TAFs promote resistance to HER2-targeted therapies. TAFs produce and secrete high levels of FGF5, which induces FGFR2 activation in the surrounding breast cancer cells. FGFR2 transactivates HER2 via c-Src, leading to res…

0301 basic medicineCancer ResearchReceptor ErbB-2medicine.medical_treatmentMice NudeBreast NeoplasmsDrug resistanceTargeted therapy03 medical and health sciencesMice0302 clinical medicineBreast cancerCancer-Associated FibroblastsTrastuzumabCell Line TumorAntineoplastic Combined Chemotherapy ProtocolsmedicineNeoplasmAnimalsHumansReceptor Fibroblast Growth Factor Type 2skin and connective tissue diseasesneoplasmsbusiness.industryLapatinibTrastuzumabmedicine.diseaseXenograft Model Antitumor AssaysSurvival Rate030104 developmental biologyOncologyTumor EscapeApoptosisDrug Resistance Neoplasm030220 oncology & carcinogenesisCancer researchFemaleSignal transductionNeoplasm Recurrence Localbusinessmedicine.drugSignal Transduction
researchProduct

Palmitoylethanolamide Promotes a Proresolving Macrophage Phenotype and Attenuates Atherosclerotic Plaque Formation

2018

Objective— Palmitoylethanolamide is an endogenous fatty acid mediator that is synthetized from membrane phospholipids by N -acyl phosphatidylethanolamine phospholipase D. Its biological actions are primarily mediated by PPAR-α (peroxisome proliferator-activated receptors α) and the orphan receptor GPR55. Palmitoylethanolamide exerts potent anti-inflammatory actions but its physiological role and promise as a therapeutic agent in chronic arterial inflammation, such as atherosclerosis remain unexplored. Approach and Results— First, the polarization of mouse primary macrophages towards a proinflammatory phenotype was found to reduce N -acyl phosphatidylethanolamine phospholipase D expression …

0301 basic medicineCannabinoid receptorTime FactorsMice Knockout ApoECHOLESTEROL TRANSPORTAnti-Inflammatory AgentsPhospholipaseProto-Oncogene Maschemistry.chemical_compoundCannabinoid receptor type 2Receptors CannabinoidAortachemistry.chemical_classificationMARROW-DERIVED CELLSAPOPTOTIC CELL ACCUMULATIONPlaque AtheroscleroticCell biologymacrophagesDENSITY-LIPOPROTEIN RECEPTORPhenotypeREDUCES INFLAMMATIONCB2 RECEPTOREthanolaminesFemaleCardiology and Cardiovascular MedicineSCAVENGER RECEPTORAortic DiseasesPalmitic Acidsta3111fatty acidsCell Line03 medical and health sciencesMediatorPhagocytosisPhospholipase DAnimalsHumansScavenger receptorCANNABINOID RECEPTORPhosphatidylethanolaminePalmitoylethanolamidec-Mer Tyrosine KinaseFatty acidcholesterolta3121AmidesRatsMice Inbred C57BLDisease Models Animal030104 developmental biologychemistryinflammationRECEPTOR CLASS-BatherosclerosisCONTACT ALLERGIC DERMATITISArteriosclerosis Thrombosis and Vascular Biology
researchProduct

Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.

2017

The neurofibromatosis type 2 (NF2) tumor suppressor protein Merlin functions as a negative regulator of cell growth and actin dynamics in different cell types amongst which Schwann cells have been extensively studied. In contrast, the presence and the role of Merlin in oligodendrocytes, the myelin forming cells within the CNS, have not been elucidated. In this work, we demonstrate that Merlin immunoreactivity was broadly distributed in the white matter throughout the central nervous system. Following Merlin expression during development in the cerebellum, Merlin could be detected in the cerebellar white matter tract at early postnatal stages as shown by its co-localization with Olig2-positi…

0301 basic medicineCentral Nervous SystemCytoplasmlcsh:MedicineNervous SystemMyelinMiceCell MovementAnimal CellsCerebellumMedicine and Health SciencesNeurofibromatosis type 2lcsh:ScienceNeuronsStainingCerebral CortexNeurofibromin 2MultidisciplinarybiologyCell StainingBrainCell migrationCell biologyOligodendrogliamedicine.anatomical_structureGenetic DiseasesCell ProcessesAnatomyCellular TypesCellular Structures and OrganellesResearch ArticleCell typeNeurofibromatosis 2NeurogenesisNerve Tissue ProteinsTransfectionResearch and Analysis MethodsCell Line03 medical and health sciencesmedicineAnimalsImmunohistochemistry TechniquesCell ProliferationCell NucleusClinical GeneticsCell growthAutosomal Dominant Diseaseslcsh:RBiology and Life SciencesCell Biologymedicine.diseaseOligodendrocyteMyelin basic proteinMerlin (protein)Mice Inbred C57BLHistochemistry and Cytochemistry Techniques030104 developmental biologySpecimen Preparation and TreatmentAstrocytesNeurofibromatosis Type 2Cellular Neurosciencebiology.proteinImmunologic Techniqueslcsh:QSchwann CellsNeurosciencePLoS ONE
researchProduct

Use of Troponin as a predictor for cardiovascular diseases in patients with type 2 Diabetes Mellitus

2020

People with type 2 diabetes mellitus (T2DM) have two- to four-fold increased cardiovascular mortality in comparison to the general population. With the identification of new therapeutic targets and hypoglycemic drugs for T2DM, the need for a better stratification of CVD risk has emerged to select patients who may need intensive or specific treatment. At present, risk stratification is based on clinical, demographic, and biochemical factors. High sensitivity cardiac troponin (hs-cTn) increases after several ischemic and non-ischemic insults and it is considered a marker of myocardial injury. This review summarizes the main findings about hs-cTn utilization for risk stratification in people w…

0301 basic medicineDiabetes mellitumedicine.medical_specialtyendocrine system diseasesClinical BiochemistryPopulationSettore MED/49Biochemistrylaw.invention03 medical and health sciencesDiabetes mellitus0302 clinical medicineRandomized controlled triallawDiabetes mellitusmedicineHumansIn patientIntensive care medicineeducationLife StyleCardiovascular mortalityClinical Trials as Topiceducation.field_of_studyPrimary preventionbiologybusiness.industryBiochemistry (medical)Type 2 Diabetes MellitusBiomarkerGeneral MedicineCardiovascular diseasePrognosismedicine.diseaseTroponinTroponinSettore BIO/12 - Biochimica Clinica E Biologia Molecolare Clinica030104 developmental biologyRisk factorsDiabetes Mellitus Type 2Cardiovascular Diseases030220 oncology & carcinogenesisbiology.proteinObservational studyRisk factorbusinessBiomarkersClinica Chimica Acta
researchProduct

AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions

2017

Abstract This review summarizes our current understanding of nonalcoholic fatty liver disease (NAFLD), a multi-factorial systemic disease resulting from a complex interaction between a specific genetic background and multiple environmental/metabolic “hits”. The role of gut microbiota, lipotoxicity, inflammation and their molecular pathways is reviewed in-depth. We also discuss the epidemiology and natural history of NAFLD by pinpointing the remarkably high prevalence of NAFLD worldwide and its inherent systemic complications: hepatic (steatohepatitis, advanced fibrosis and cirrhosis), cardio-metabolic (cardiovascular disease, cardiomyopathy, arrhythmias and type 2 diabetes) and neoplastic (…

0301 basic medicineDiagnostic ImagingLiver Cirrhosismedicine.medical_specialtyCirrhosisEpidemiologySettore MED/12 - GASTROENTEROLOGIAPhysiopathologyNatural historyType 2 diabetesDiseaseDiagnosis; Epidemiology; Genetics; Management; Natural history; PhysiopathologyBioinformaticsGastroenterology03 medical and health sciences0302 clinical medicineGeneticNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseaseDiagnosismedicineGeneticsHumansmedicine.diagnostic_testHepatologyDiagnosis; Epidemiology; Genetics; Management; Natural history; Physiopathology; Hepatology; Gastroenterologybusiness.industryLiver NeoplasmsGastroenterologyHepatologymedicine.diseaseManagement030104 developmental biologyLipotoxicityDiabetes Mellitus Type 2LiverCardiovascular DiseasesLiver biopsy030211 gastroenterology & hepatologySteatohepatitisbusinessBiomarkersDiagnosi
researchProduct

Effects of quality and quantity of protein intake for type 2 Diabetes Mellitus prevention and metabolic control

2020

Purpose of Review: The aim of this review is to evaluate the ideal protein quality and quantity and the dietary composition for the prevention and metabolic control of type 2 diabetes mellitus (T2DM). Introduction: Although some reviews demonstrate the advantages of a diet with a higher protein intake, other reviews have observed that a diet high in carbohydrates, with low-glycaemic index carbohydrates and good fibre intake, is equally effective in improving insulin sensitivity. Methods: Over 2831 articles were screened, and 24 from the last 5 years were analysed and summarised for this review, using the protein, diabetes and insulin glucose metabolic keywords in Pubmed in June 2019. Result…

0301 basic medicineDietary FiberMeatDatabases Factualmedicine.medical_treatmentPhysiology030209 endocrinology & metabolismType 2 diabetesDiet; Intake; Protein; Quality; Type 2 diabetesSettore MED/4903 medical and health sciencesEating0302 clinical medicineSettore MED/13Diabetes mellitusmedicineAnimalsHumansMetabolic Syndrome030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryInsulinProteinType 2 Diabetes MellitusProteinsType 2 diabetesmedicine.diseaseQualityDietDiabetes Mellitus Type 2Plant proteinGlycemic IndexMetabolic control analysisIntakeDairy ProductsMetabolic syndromeInsulin ResistancebusinessProtein qualityFood Science
researchProduct

A Physiology-Based Model of Human Bile Acid Metabolism for Predicting Bile Acid Tissue Levels After Drug Administration in Healthy Subjects and BRIC …

2019

Drug-induced liver injury (DILI) is a matter of concern in the course of drug development and patient safety, often leading to discontinuation of drug-development programs or early withdrawal of drugs from market. Hepatocellular toxicity or impairment of bile acid (BA) metabolism, known as cholestasis, are the two clinical forms of DILI. Whole-body physiology-based modelling allows a mechanistic investigation of the physiological processes leading to cholestasis in man. Objectives of the present study were: (1) the development of a physiology-based model of the human BA metabolism, (2) population-based model validation and characterisation, and (3) the prediction and quantification of alter…

0301 basic medicineEXPRESSIONPBPKLIVERmedicine.drug_classPhysiologyBenign Recurrent Intrahepatic CholestasisPopulationBIOMARKERScomputational modellingPhysiologyDIAGNOSISlcsh:Physiology03 medical and health scienceschemistry.chemical_compoundPHARMACOKINETIC MODEL0302 clinical medicineCholestasisPhysiology (medical)Glycochenodeoxycholic acidMedicineddc:610educationEnterohepatic circulationKINETICSOriginal ResearchLiver injuryINTRAHEPATIC CHOLESTASISbile acidseducation.field_of_studyBile acidlcsh:QP1-981business.industryBRIC type 2medicine.diseaseTRANSPORTERS3. Good health030104 developmental biologychemistryToxicitySIMULATION030211 gastroenterology & hepatologyENTEROHEPATIC CIRCULATIONDILIbusinesscholestasisFrontiers in Physiology
researchProduct